ArticleOrphanet journal of rare diseases2026
Cost analysis of hospitalized children suspected of rare genetic diseases.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundConventional genetic tests (CGT) are currently employed in Canada to investigate rare genetic disorders (RGD) but costs related to their use have been scarcely examined. We aimed to estimate the total hospital costs for children suspected of having rare genetic diseases.
methodsThis was a retrospective study based on the patients’ medical records. The analysis adopted the hospital’s perspective and the total hospitalization cost was assessed using an inhospital cost database, which included direct costs (e.g., lab tests, drugs), and indirect costs (e.g., hospital overheads). We provide mean costs with 95% confidence intervals obtained with bootstrap analyses.
resultsData from a total of 223 children were analyzed. Mean age was 3.0 years and 119 (53.4%) were male. The average length of hospital stay was 42 days. The mean hospitalization cost per patient in the CGT cohort was $170,337 (95% CI. 128,231 − 219,277). The cost for newborns (0–30 days), $219,498 (95% CI. 144,061–312,395), was higher than for other age categories (p = 0.0914).
conclusionHospitalization costs for the CGT cohort were substantially greater than hospitalization costs for the general pediatric population. Subgroup analyses revealed that newborns investigated with CGT were the most expensive among all pediatric cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.